Select Bibliography

Select Bibliography

Filter by any of these (after searching):

Federally Funded Research

There are 901 items

Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Google Scholar

Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)

DOI

Google Scholar

Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Google Scholar

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer.

Google Scholar

Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326

Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198.

Google Scholar

Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - NCCTG-N0026

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Google Scholar

Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Google Scholar

Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

DOI

Google Scholar

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - AFT-19

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)

Google Scholar

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series

Google Scholar

Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687

Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance)

Google Scholar

Al-Refaie, Waddah B. , Decker, Paul A. , Pisters, Peter W.T. ... - SSO - Ann. Surg. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Older Adult - Z901101

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

Google Scholar

Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Google Scholar

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J

Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

Google Scholar

Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Google Scholar

Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0147

Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver.

Google Scholar

Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945

Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

Google Scholar

Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849

ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial

Google Scholar

Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503)

Google Scholar

Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503

Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).

Google Scholar

Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0776

Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902.

Google Scholar

Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902

Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset.

Google Scholar

Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441

Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma

Google Scholar

Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682

External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.

Google Scholar

Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102

Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Google Scholar

Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - A031501

Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.

Google Scholar

Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338

Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection

Google Scholar

Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance)

Google Scholar

Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305

DOI

Google Scholar

Armer, Jane M , Liu, Heshan , Oliveri, Jill , Seisler, Drew , tbd ... - ASCO CSS - J. Clin. Oncol. - 2018

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - CALGB-70305

Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors

Google Scholar

Arnold, Kristen , Andridge, Rebecca , Logan, Amanda , Yee, Lisa ... - EB - FASEB J - 2015

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - NCT01478477

Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

Google Scholar

Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N0993

Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])

Google Scholar

Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Google Scholar

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Google Scholar

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502

A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.

Google Scholar

Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461

Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720)

Google Scholar

Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720

Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies

Google Scholar

Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720

Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia

Google Scholar

Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720

Google Scholar

Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720

Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators

Google Scholar

Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0148

A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804

Google Scholar

Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804

A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9

Google Scholar

Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9

Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2

Google Scholar

Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2

Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7

Google Scholar

Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C7

Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance)

Google Scholar

Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3

Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance)

Google Scholar

Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3

A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA

Google Scholar

Barton, D. L. , Soori, G. S. , Bauer, B. , Sloan, J. , Johnson, P. A. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA

A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA

Google Scholar

Barton, D. L. , Wos, E. , Qin, R. , Mattar, B. , Green, N. , Lanier, K. ... - - J. Clin. Oncol. - 2009

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA

Adiponectin: A novel biomarker for cancer- related fatigue?; NCCTG study N07C2 (Alliance)

Google Scholar

Barton, D. , Liu, H. , Tan, A. , Sloan, J. ... - MASCC / ISOO - Support Care Cancer - 2013

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N07C2

Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)

Google Scholar

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1

Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance)

Google Scholar

Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014

Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML)

Google Scholar

Becker, H. , Marcucci, G. , Maharry, K. , Margeson, D. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns

Google Scholar

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - - Haematologica - 2010

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720

Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Google Scholar

Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GI - A021202

High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials

Google Scholar

Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007

Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581

Google Scholar

Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - GI - C9581

Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study.

Google Scholar

Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103

Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials

Google Scholar

Beutler, A. S. , Kulkarni, A. , Kanwar, R. , Qin, R. ... - AACR - AACR 2013 Annual Meeting - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - N08C1 , N08CA

Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance)

Google Scholar

Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance)

Google Scholar

Bhongsatiern, Jiraganya , Carbonetto, P. , Chua, Katherina C. ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502

Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance)

Google Scholar

Bill, Marius , Eisfeld Ann-Kathrin , Mrózek Krzysztof ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols

DOI

Google Scholar

Bill, Marius , Mrózek, K , Kohlschmidt, J. , Nicolet, D. ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , CALGB-9665

A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance)

DOI

Google Scholar

Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461

Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML)

DOI

Google Scholar

Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , C9665 , CALGB-20202

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105

Google Scholar

Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105

Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials

Google Scholar

Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741

Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer.

Google Scholar

Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51

Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Google Scholar

Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Google Scholar

Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502

Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Google Scholar

Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904

Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study

Google Scholar

Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010

Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-10503

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Google Scholar

Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503

Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study.

Google Scholar

Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904

Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)

Google Scholar

Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153

Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Google Scholar

Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071

Google Scholar

Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial

Google Scholar

Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance)

Google Scholar

Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance)

Google Scholar

Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance)

Google Scholar

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071

Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

DOI

Google Scholar

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Google Scholar

Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Google Scholar

Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer

Google Scholar

Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration

Google Scholar

Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401.

Google Scholar

Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Neuro-Onc - A071401

A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)

Google Scholar

Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Google Scholar

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Google Scholar

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Google Scholar

Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C

Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

Google Scholar

Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

Google Scholar

Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041

ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

Google Scholar

Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer

DOI

Google Scholar

Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

Google Scholar

Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741

Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741.

Google Scholar

Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741

Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633

Google Scholar

Capelletti, M. , Wang, X. F. , Gu, L. , Graziano, S. L. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9633

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Google Scholar

Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Google Scholar

Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - C40601

Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies

Google Scholar

Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC)

Google Scholar

Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

Google Scholar

Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441

Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

Google Scholar

Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392

Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

Google Scholar

Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Google Scholar

Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Google Scholar

Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Google Scholar

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary Endpoint - Primary Analysis - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Google Scholar

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary Endpoint - Primary Analysis - GU - A031203

Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance)

Google Scholar

Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40101 , CALGB-40502

Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials

Google Scholar

Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9831 , NSABP B-31

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Google Scholar

Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Google Scholar

Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)

Google Scholar

Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303

Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52

Google Scholar

Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Acute Myeloid Leukemia (AML) with 9q aberrations occuring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)

Google Scholar

Corbacioglu, A. , Frohling, S. , Paschka, P. , Marcucci, G. ... - ASH - Blood - 2007

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-8461 , CALGB-9621 , CALGB-9665

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001

Google Scholar

Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

Google Scholar

Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC)

Google Scholar

Cuffe, S. , Ezzalfani, M. , Bourredjem, A. , Graziano, S. L. ... - Chicago MSTO - - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC).

Google Scholar

Cuffe, S. , Graziano, S. , Bourredjem, A. , Pignon, J. P. ... - - J Thorac Oncol - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

The Feasibility of Radiotherapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial.

DOI

Google Scholar

Cuttino, Laurie , McCall, Linda , Kubicky, C , Ballman, Karla ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019

Abstract - Secondary Endpoint - Primary Analysis - Prevention - Z11102

A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402

Google Scholar

Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]

Google Scholar

Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008

Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402

p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

Google Scholar

D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682

Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Google Scholar

D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103

The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761

Google Scholar

D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761

Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

Google Scholar

Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

Google Scholar

Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)

DOI

Google Scholar

Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset

Google Scholar

De Gramont, A. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - GI - N0441

Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance)

Google Scholar

DeBoer, Rebecca , Mulkey, Flora , Koval, Gregory , Wetzler, Meir ... - EHA - Haematologica - 2014

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001 , CALGB-9665

Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

Google Scholar

Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000

Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

Google Scholar

Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

Google Scholar

Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007

Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657)

Google Scholar

Demichele, A. , Yau, C. , Zhu, J. , Wuhfkuhle, J. , Lenburg, M. E. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007

In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions

Google Scholar

Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102

Hypothetical double-consent design intervention

Google Scholar

Demmy, T. L. , Kohman, L. J. ... - CTAS - - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30102 , CALGB-9334

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Google Scholar

Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103

Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Google Scholar

Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma

Google Scholar

Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102

Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial.

Google Scholar

Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - NCCTG-N0723

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Google Scholar

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Google Scholar

Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013

Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087

Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality Assurance Review of ACOSOG Z-4032

Google Scholar

Dipetrillo, T. A. , Heron, D. E. , Landreneau, R. J. , Logan, D. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM)

Google Scholar

Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675

CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)

Google Scholar

Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601

Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

DOI

Google Scholar

Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901

Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Google Scholar

Dueck, A. C. , Mendoza, T. R. , Mitchell, S. A. , Reeve, B. B. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - Comprehensive

Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials.

Google Scholar

Dueck, A. , Sargent, D. , Novotny, P. , Decker, P. , Nelson, H. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - N0591

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Google Scholar

Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT)

DOI

Google Scholar

Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015

Abstract - Secondary Endpoint - Primary Analysis - GI - N1048

Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer)

DOI

Google Scholar

Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031

Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial

DOI

Google Scholar

Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Google Scholar

Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528

N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)

Google Scholar

Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821

Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603)

DOI

Google Scholar

Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study

Google Scholar

Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603

A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Google Scholar

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

DOI

Google Scholar

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

DOI

Google Scholar

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304

Google Scholar

Edelman, M. J. , Hodgson, L. D. , Wang, X. , Christenson, R. H. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203

Google Scholar

Edelman, M. J. , Watson, D. M. , Wang, X. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203

Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)

Google Scholar

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801

Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

Google Scholar

Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011

Abstract - Primary Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621

Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

DOI

Google Scholar

Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ALTTO

Additional gene mutations refine the 2017 European Leukemianet (ELN) classification of adult patients (pts) with de novo acute myeloid leukemia (AML) aged <60 years: An analysis of Alliance studies

DOI

Google Scholar

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Mutations in genes associated with familial predisposition to myeloid neoplasms:their frequency and associations with pretreatment characteristics in adult patients (pts) with presumably sporadic de novo acute myeloid leukemia (AML) (Alliance)

DOI

Google Scholar

Eisfeld, Ann-Kathrin , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202

Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML)

Google Scholar

Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665

MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML)

Google Scholar

Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

Google Scholar

Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

Google Scholar

Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B

Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders

DOI

Google Scholar

Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - - Cancer Research - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031

CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

Google Scholar

Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80403

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657)

Google Scholar

Esserman, L. J. , Perou, C. M. , Cheang, M. , Demichele, A. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

DOI

Google Scholar

Fadelu, Temidayo , Sui Zhang , Donna Niedzwiecki , Xing Ye ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

Google Scholar

Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100101

Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)

Google Scholar

Federico Innocenti , Heinz-Josef Lenz , Jeffrey Meyerhardt ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Google Scholar

Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials

DOI

Google Scholar

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601

Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study

Google Scholar

Fernando, H. C. , Landreneau, R. J. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 91st Annual Meeting - 2011

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

Google Scholar

Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - ACOSOG-Z4032

Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Google Scholar

Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Factors contributing to cancer screening in African Americans

Google Scholar

Ferrans, C. E. , Ryan, C. , Archer, L. E. , Freels, S. , Lan, L. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-119901

Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710

Google Scholar

Feusner, J. , Gregory, J. , Moser, B. K. , Hars, V. , Powell, B. L. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710

Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)

Google Scholar

Fibla, J. J. , Cassivi, S. D. , Decker, P. A. , Allen, M. S. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

DOI

Google Scholar

Fleming, Gini F , Francis, Prudence A , Láng, István ... - SABCS - Ann. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer

Google Scholar

Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - INT-0146

Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)

Google Scholar

Foster, Jared C. , Le-Rademacher, Jennifer G. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151602 , ACOSOG-Z9001 , NCCTG-97-24-51

Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group.

Google Scholar

Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation.

Google Scholar

Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424

Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Google Scholar

Foster, N. R. , Qi, Y. , Krook, J. E. , Kugler, J. W. , Kuross, S. A. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - N0424

Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Google Scholar

Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0424

Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis

Google Scholar

Foster, N. R. , Renfro, L. A. , Schild, S. E. , Redman, M. W. ... - - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - Comprehensive , CALGB-9033 , CALGB-9732 , CALGB-30103 , NCCTG-862051 , NCCTG-892051 , NCCTG-932053 , ECOG-1500 , ECOG-7593 , JCOG-9511 , NCIC-BR4 , NCIC-BR8 , SWOG-S0124

Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials.

Google Scholar

Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - N994C

Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer

DOI

Google Scholar

Francis, Prue , Fleming, Gini , Regan, Meredith , Pagani, Olivia ... - SABCS - Cancer Res - 2017

Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841.

Google Scholar

Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741

Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907

Google Scholar

Freedman, R. , Pitcher, B. , Keating, N. , Barry, W. , Ballman, K. ... - - Cancer Res. - 2012

Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527 (Multiple)

Google Scholar

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Comprehensive Analysis - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers.

Google Scholar

French, A. , Sinicrope, F. , Foster, N. , Thibodeau, S. , Sargent, D. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N994C

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Google Scholar

Friday, B. B. , Buckner, J. , Anderson, S. K. , Giannini, C. ... - SNO - 15th Annual Meeting of the Society for Neuro-Oncology (SNO) - 2010

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779

Dietary and lifestyle determinants of colon cancer recurrence and survival

Google Scholar

Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - GI - C89803

KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803

Google Scholar

Fuchs, C. S. , Ogino, S. , Meyerhardt, J. A. , Irahara, N. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - GI - C89803

Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101

Google Scholar

Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80101

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Google Scholar

Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013

Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50403

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side.

Google Scholar

Furchtgott, Leon , Swanson, David , Hayete, Boris , Khalil, Iya ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]

Google Scholar

Gajra, Ajeet , McCall, Linda , Muss, Hyman B. , Cohen, Harvey J. ... - SABCS - Cancer Res. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Google Scholar

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - - Neuro-oncology - 2011

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

Google Scholar

Galanis, E. , Jaeckle, K. A. , Maurer, M. J. , Reid, J. M. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047B

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

Google Scholar

Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776

Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development.

Google Scholar

Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - - Ann. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Google Scholar

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710

Google Scholar

Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710

Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial

Google Scholar

Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R. J. , Chan, E. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

Google Scholar

George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-90206

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

Google Scholar

George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203

Central Pathology Review by Whole Slide Imaging in Glioblastoma Clinical Trials

Google Scholar

Giannini, Caterina , Miller, Ryan , Ligon, Keith , Tollefson, Helen ... - AANP - J Neuropathol Expl Neurol - 2015

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - N0872 , N0877

Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).

Google Scholar

Gill, S. , Loprinzi, C. , Kennecke, H. , Grothey, A. , Nelson, G. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0148

Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial

Google Scholar

Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. W. ... - ASA - American Surgical Association 130th Annual Meeting - 2010

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node

Google Scholar

Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Ten-Year Survival Results of ACOSOG Z0011 (Alliance)

Google Scholar

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial

Google Scholar

Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - ASA - - 2016

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52.

Google Scholar

Goetz, M. P. , Moyer, A. M. , Weinshilboum, R. M. , Suman, V. A. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52

Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance)

Google Scholar

Goetz, M. , Foster, N. , Meyers, J. , Steen, P. , Visscher, D. ... - - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0871

Tamoxifen Pharmacogenetics of CYP2D6, CYP2C19, and SULTIA1: Long Term Follow-up of the North Central Cancer Treatment Group 89-30-52 Adjuvant Trial.

Google Scholar

Goetz, M. , Suman, V. , Ames, M. , Black, J. , Safgren, S. , Kuffel, M. ... - - Cancer Res. - 2009

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - PPP - NCCTG-89-30-52

A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in 9 first line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC).

Google Scholar

Goldberg, R. M. , Kohne, C. H. , Seymour, M. T. , De Gramont, A. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N0545 , N9741

Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

Google Scholar

Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N0147

Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance)

Google Scholar

Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N1048

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance).

Google Scholar

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald A. ... - ASA - - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603

Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Google Scholar

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603

Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL

Google Scholar

Gomez, R. , Zakhireh, J. , Moore, D. , Demichelle, A. , Przewoznik, J. ... - SABCS - Cancer Res. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Survival Outcomes from CALGB 80803 (Alliance): A Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer

DOI

Google Scholar

Goodman, Karyn A. , Hall, Nathan , Bekaii-Saab, Tanios , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2018

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80803

Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Google Scholar

Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80803

Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience

Google Scholar

Gordon, David , Liu, Qianying , Kleinman, Benjamin ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - Comprehensive

Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

DOI

Google Scholar

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091105

Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407

Google Scholar

Govindan, R. , Bogart, J. A. , Wang, X. , Hodgson, L. D. ... - - J. Clin. Oncol. - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30407

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

Google Scholar

Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - CALGB-30407

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Google Scholar

Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50701

Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633

Google Scholar

Graziano, S. L. , Gu, L. , Wang, X. , Tatum, A. , Vollmer, R. T. ... - - J Thorac Oncol - 2007

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159802 , CALGB-9633

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

Google Scholar

Graziano, S. L. , Pignon, J. P. , Vollmer, R. T. , Kratzke, R. A. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633

Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

Google Scholar

Graziano, S. L. , Socinski, M. A. , Herndon, J. E., 2nd ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901

LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by Immunohistochemistry (IHC) in patients with resected Non-Small Cell Lung Cancer (NSCLC).

Google Scholar

Graziano, S. , Paris, E. , Ma, X. , Pignon, J. , Hainaut, P. ... - - Ann. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)

Google Scholar

Green, M. R. , Miller, A. A. , Wang, X. , Gu, L. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30303

Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984

Google Scholar

Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984

Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial

Google Scholar

Grogan, E. , Deppen, S. , Ballman, K. , Andrade, G. , Verdail, F. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

New lesions vs. growth of existing disease: does it impact prognosis?

Google Scholar

Grothey, A. , Heun, J. M. , Branda, M. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

Google Scholar

Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N054C

Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC)

Google Scholar

Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

DOI

Google Scholar

Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - CALGB-80702

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Google Scholar

Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017

Abstract - Secondary Endpoint - Preliminary Analysis - GI - CALGB-80405

Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

DOI

Google Scholar

Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang-Shu ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer (Alliance)

Google Scholar

Guercio, Brendan J. , Zhang, Sui , Venook, Alan P. , Ou, Fang-Shu ... - AACR - Cancer Res - 2019

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405

Dual Epigenetic Control of CCAAT/Enhancer Binding Protein {alpha} (C/EBP{alpha}) Expression in Acute Myeloid Leukemia

Google Scholar

Hackanson, B. , Bennett, K. L. , Brena, R. M. , Jiang, J. ... - - Blood - 2007

Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665

Persistent Fatigue in Stem Cell Transplant Survivors: A Biobehavioral Perspective

Google Scholar

Hacker, Eileen Danaher , Fink, Anne , Peters, Tara , Park, Chang ... - ONS - Biol. Blood Marrow Transplant. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - Pilot

Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.

Google Scholar

Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0349

Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance]

Google Scholar

Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - ASTRO - Int J Radiation Biol Physics - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (Alliance)

Google Scholar

Haffty, Bruce , Ballman, Karla , Hunt, Kelly , McCall, Linda ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

Google Scholar

Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Google Scholar

Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Google Scholar

Halabi, S. , Ou, S. , Vogelzang, N. J. , Scher, H. I. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - Comprehensive

Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Google Scholar

Halabi, S. , Rini, B. I. , Stadler, W. M. , Archer, L. E. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206

Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

Google Scholar

Halabi, S. , Vogelzang, N. J. , Kornblith, A. B. , Archer, L. E. ... - ASCO GU - Genitourinary Cancers Symposium - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - C9181 , C9182 , INT-0159

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Google Scholar

Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - CALGB-90401 , S9916

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

DOI

Google Scholar

Halabi, Susan , Lin, Chen-Yen , Small, Eric J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer

Google Scholar

Haluska, P. , Reinholz, M. M. , Dueck, A. C. , Linden, H. M. ... - - J. Clin. Oncol. - 2010

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - N0733

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Google Scholar

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N0733

Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study.

Google Scholar

Halyard, M. Y. , Dueck, A. C. , Pisansky, T. M. , Mclaughlin, S. A. ... - SABCS - Cancer Res. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy

Google Scholar

Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-89-20-52

Changes in left ventricular function after radiation therapy and trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial N9831.

Google Scholar

Halyard, M. , Pisansky, T. M. , Pierce, L. J. , Solin, L. J. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831

Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031

Google Scholar

Harpole, D. , Ballman, K. V. , Oberg, A. L. , Whiteley, G. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis

Google Scholar

Harris, L. N. , Parker, J. R. , Broadwater, G. , Schulz, V. ... - - Cancer Res. - 2009

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - CALGB-9342 , CALGB-9840 , CALGB-159806

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Google Scholar

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Google Scholar

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206

Application of 2008 WHO classification criteria for myelodysplastic syndromes (MDS) without excess blasts: Observations from Cancer and Leukemia Group B Study 10105

Google Scholar

Hasserjian, R. , Gupta, P. , Donohue, K. A. , Owzar, K. ... - USCAP - United States and Canadian Academy of Pathology Annual Meeting - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10105

A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803

Google Scholar

Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012

Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)

Google Scholar

Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Google Scholar

Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

Google Scholar

Heinemann, Volker , Niedzwiecki, Donna , Pearline, Rachel ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405

CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Google Scholar

Heist, R. C. Suk , Wang, X. , Hodgson, L. D. , Otterson, G. A. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

DOI

Google Scholar

Hensing, Thomas , Wang, Xiaofei , Kozono, David , Dudek, Arkadius ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-09

A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance)

Google Scholar

Hertz, D. L. , Owzar, K. , Halabi, S. , Kelly, W. K. , Zembutsu, H. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C90401 , CALGB-60404

A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Google Scholar

Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Google Scholar

Himelstein, Andrew L. , Qin, Rui , Novotny, Paul J. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - CALGB-70604

Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Google Scholar

Ho, Alan L , Foster, Nathan R. , Meyers, Jeffrey P. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091104

Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

DOI

Google Scholar

Ho, Alan Loh , Foster, Nathan R. , Zoroufy, Alex J. , Worden, Francis ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091404

Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without+/- lapatinib (L) for HER2-positive breast cancer

Google Scholar

Hoadley, Katherine A. , Barry, William T. , Pitcher, Brandelyn N. ... - SABCS - Cancer Res - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Google Scholar

Hoadley, Katherine A. , Hyslop, Terry , Fan, Cheng , Berry, Donald A. ... - SABCS - Cancer Res - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40603

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

Google Scholar

Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0436

A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane.

Google Scholar

Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Google Scholar

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Myeloma - CALGB-100104

Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

Google Scholar

Holtan, S. G. , Foster, N. R. , Erlichman, C. E. , Aubry, M. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N004E

Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter?

Google Scholar

Hoskins, J. M. , Goldberg, R. M. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - N9741

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Google Scholar

Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50103

Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study

Google Scholar

Hsi, E. , Jung, S. , Lai, R. , Johnson, J. , Cook, J. , Jones, D. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Lymphoma - CALGB-59909

Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147

Google Scholar

Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary Endpoint - Primary Analysis - GI - N0147

Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147

Google Scholar

Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147

Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745

Google Scholar

Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N0745

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

Google Scholar

Hughes, K. S. , Schnaper, L. , Cirrincione, C. T. , Berry, D. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-9343

Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

Google Scholar

Hume, C. Bueno , Moreno-Aspitia, A. , Hillman, D. , Chen, B. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N083E

A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071

Google Scholar

Hunt, K. , Le-Petross, H. T. , Suman, V. , Haffty, B. G. ... - - J. Clin. Oncol. - 2010

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - ACOSOG-Z1071

Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)

Google Scholar

Hunt, Kelly K. , Suman, Vera J. , Meric-Bernstam, Funda ... - SSO - Ann Surg Oncol - 2019

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance)

Google Scholar

Hurwitz, H. , Cushman, S. , Jiang, C. , Shterev, I. , Mahoney, M. R. ... - - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203

Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903

DOI

Google Scholar

Hwang, E. Shelley , Duong, Stephanie , Bedrosian, Isabelle ... - SABCS - Cancer Res - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40903

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007

Google Scholar

Hylton, N. M. , Blume, J. , Gastonis, C. , Gomez, R. , Bernreuter, W. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACRIN-6657 , CALGB-150007

Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603

Google Scholar

Iglesia, Michael D. , Vincent, Benjamin G. , Serody, Jonathan S. ... - SABCS - Cancer Res. - 2014

Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603

A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?

DOI

Google Scholar

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - SSO - Ann. Surg. Oncol. - 2018

Abstract - Primary Endpoint - Primary Analysis - Disparities - Pilot

A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?

Google Scholar

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - ASCO GI - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Disparities - Pilot

Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303

Google Scholar

Innocenti, F. , Owzar, K. , Cox, N. J. , Evans, P. , Kubo, M. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303

A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients

Google Scholar

Innocenti, F , Jiang, C , Sibley, A B , Denning, S , Etheridge, A S ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303

Genetic prediction of VEGF-A plasma levels in cancer patients CALGB 80303 (Alliance)

Google Scholar

Innocenti, Federico , Jiang, Chen , Sibley, Alexander ... - AACR - Cancer Res - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80303

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Google Scholar

Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405

The vitamin D receptor gene is a determinant of survival in advanced pancreatic cancer patients

Google Scholar

Innocenti, Federico , Owzar, Kouros , Jiang, Chen , Seiser, Eric ... - ECC - - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80303

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Google Scholar

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80405

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Google Scholar

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ECC - Eur J Cancer - 2015

Abstract -